Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNiox Group Regulatory News (NIOX)

Share Price Information for Niox Group (NIOX)

Share Price is delayed by 15 minutes
Get Live Data
61.00    2.00 (3.39%)
Bid:
60.40
Ask:
61.80
Spread: 1.40 (2.318%)
Market Cap: £256.73m
NIOX Live PriceLast checked at - London Stock Exchange

Intraday Niox Group Share Chart

Statement regarding NIOX Group Plc

11 Apr 2025 07:00

RNS Number : 6002E
Keensight Capital SAS
11 April 2025
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

 

THIS IS AN ANNOUNCEMENT TO WHICH RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") APPLIES.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

 

FOR IMMEDIATE RELEASE

 

 

11 April 2025

 

Keensight Capital

 

Statement regarding NIOX Group plc

 

Further to the announcement made by NIOX Group plc ("NIOX") regarding a possible cash offer for NIOX by Keensight Capital ("Keensight"), Keensight confirms that, in light of the current macro-economic backdrop, it does not intend to make a firm offer for NIOX. Consequently, Keensight is bound by the restrictions set out under Rule 2.8 of the Code, except with the consent of the Panel.

 

Under Note 2 on Rule 2.8 of the Code, Keensight and any person acting in concert with Keensight, reserve the right to set aside the restrictions in Rule 2.8 in the following circumstances: (i) with the agreement of the Board of NIOX; (ii) if a third party announces a firm intention to make an offer for NIOX; (iii) if NIOX announces a Rule 9 waiver proposal (see Note 1 of the Notes on Dispensations from Rule 9) or a reverse takeover (as defined in the Code); or (iv) if there has been a material change of circumstances (as determined by the Panel on Takeovers and Mergers).

 

Keensight, on behalf of its managed funds, and any person acting in concert with Keensight, reserves the right to acquire and/or offer to acquire NIOX shares or interests in NIOX shares subject to and in accordance with the Code (including Rule 2.8) and other applicable regulations.

 

 

Enquiries:

 

Keensight Capital

+44 (0) 20 4558 5441

Amit Karna

Michael Healy

Susanna Mestriner

 

LEI Number: 9695002S0E6MOJMK5104

 

UBS AG London Branch (Financial Adviser to Keensight)

 

+44 (0) 20 7567 8000

Craig Calvert

Ian Hart

Paul Finlayson

Anisah Mahomed

Headland Consultancy (PR adviser to Keensight)

+44 (0)20 3805 4822

Del Jones

Stephanie Ellis

 

The person(s) responsible for arranging release of this announcement on behalf of Keensight are Cindy Giraud, Communications Director and Stephanie Ellis (Headland Consultancy).

About Keensight Capital

Keensight Capital ("Keensight"), one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. With over 25 years of experience and €5.5bn of assets under management, Keensight Capital's team of seasoned professionals leverages their differentiated private equity experience to invest in profitably growing companies generating revenues in the range of €10 million to €400 million. Drawing on its expertise in the Technology and Healthcare sectors, Keensight identifies the best investment opportunities in Europe and works closely with the management teams providing capital, strategic guidance and operational support. Keensight operates in more than 90 countries across the globe with a presence in Paris, London, Boston, and Singapore.

 

Important notices relating to advisers

 

UBS AG London Branch ("UBS") is authorised and regulated by the Financial Market Supervisory Authority in Switzerland. It is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority in the United Kingdom. UBS is acting as Adviser to Keensight and no one else in connection with the matters set out in this announcement. In connection with such matters, UBS, its affiliates, and its or their respective directors, officers, employees and agents will not regard any other person as its client, nor will it be responsible to any other person for providing the protections afforded to its clients or for providing advice in relation to the contents of this announcement or any other matter referred to herein.

 

Ropes & Gray International LLP is retained as legal adviser to Keensight.

This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities whether pursuant to this announcement or otherwise.

 

The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.

 

Publication on a website

 

A copy of this announcement will be made available, subject to certain restrictions relating to persons resident in restricted jurisdictions, on Keensight's website at www.Keensight.com by no later than 12 noon (London time) on 14 April 2025 (being the business day following the date of this announcement). The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRURUKRVBUSAAR
Date   Source Headline
22nd May 202412:07 pmRNSResult of Annual General Meeting
22nd May 20247:00 amRNSAGM Statement
1st May 20247:00 amRNSTotal Voting Rights Update
29th Apr 20245:00 pmRNSGrant of SAYE options
22nd Apr 20244:37 pmRNSNotice of 2024 Annual General Meeting
5th Apr 20243:10 pmRNSDirector/PDMR Shareholding
4th Apr 20242:10 pmRNSDividend Timetable
3rd Apr 20241:00 pmRNSDirector/PDMR Shareholding
3rd Apr 20249:00 amRNSReplacement: Block listing Interim Review
2nd Apr 20245:50 pmRNSBlock listing Interim Review
2nd Apr 20241:45 pmRNSReplacement: Director/PDMR Shareholding
28th Mar 20244:45 pmRNSDirector/PDMR Shareholding
28th Mar 20243:00 pmRNSGrant of options
27th Mar 20242:00 pmRNSExercise of SAYE Options
26th Mar 20247:00 amRNSFinal Results
22nd Mar 20244:00 pmRNSBlock Admission
1st Feb 20247:00 amRNSTotal Voting Rights Update
18th Jan 20247:00 amRNSAppointment of Financial Adviser and Joint Broker
18th Jan 20247:00 amRNSFull Year Trading Update
2nd Jan 20248:30 amRNSTotal Voting Rights Update
19th Dec 20233:46 pmRNSHolding(s) in Company
1st Dec 20239:20 amRNSTotal Voting Rights Update
6th Nov 202311:44 amRNSBlock Listing Applicationn
2nd Nov 20239:00 amRNSTotal Voting Rights Update
30th Oct 202310:52 amRNSHolding(s) in Company
16th Oct 20239:58 amRNSHolding(s) in Company
11th Oct 202310:09 amRNSHolding(s) in Company
2nd Oct 20237:00 amRNSBlock Listing Interim Review
27th Sep 202310:30 amRNSHolding(s) in Company
26th Sep 20237:00 amRNSInterim Results - Ended 30 June 2023
31st Aug 20239:40 amRNSTotal Voting Rights Update
28th Jul 20231:07 pmRNSBlock Admission
18th Jul 20237:00 amRNSTrading Update
7th Jun 20237:00 amRNSReturn of Capital by way of special Dividend
19th May 202310:51 amRNSHolding(s) in Company
18th May 20233:47 pmRNSResult of AGM
18th May 20237:00 amRNSAGM Statement
19th Apr 20236:00 pmRNSNotice of AGM
31st Mar 202310:52 amRNSBlock listing Interim Review
29th Mar 20238:03 amRNSDirector/PDMR Shareholding
28th Mar 20234:04 pmRNSGrant of options
27th Mar 202312:15 pmRNSAnnual Report
24th Mar 20231:00 pmRNSBlock Admission
21st Mar 20237:00 amRNSPreliminary Results
10th Feb 20237:58 amRNSHolding(s) in Company
17th Jan 20237:00 amRNSTrading Statement
8th Nov 20224:45 pmRNSConfirmation of Capital Reduction
6th Oct 202210:45 amRNSResult of GM and Proposed Capital Reduction
30th Sep 202212:15 pmRNSReplacement: Block listing Cancellation and Review
30th Sep 20229:31 amRNSBlock Listing Cancellation and Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.